Maybe time to set up a thread for Sequitur - a full text search invariably gives you the 'George W Bush' thread (non - ...).
Thursday November 21, 10:00 am ET
NATICK, Mass., Nov. 21 /PRNewswire/ -- Sequitur, Inc. announced today that it has reached an agreement to provide Genentech (NYSE: DNA - News) with access to its functional genomics technology. Sequitur will provide antisense/RNAi compounds and methods to Genentech for use in its target validation studies.
Sequitur's proprietary functional genomics technology accelerates drug discovery by helping to identify the triggers of disease. Sequitur's technology is a tool for determining the function of the human genetic code. Antisense/RNAi can help to determine gene function and validate small molecule drug targets by specifically inhibiting gene expression. Sequitur's Functional Genomics Program offers second and third generation antisense compounds (including RNAi), collaborative research and cell transfection optimization.
"We are gratified to sign this agreement with Genentech," said Tod Woolf, Sequitur's President. "This agreement validates the potential our functional genomics technology has in aiding drug discovery research."
Sequitur is a privately held corporation that offers products and services to modulate and detect gene expression. Sequitur also offers collaborations to develop therapeutic RNAi compounds. Sequitur's other clients include Bristol-Myers Squibb, Incyte Genomics, Amgen, GlaxoSmithKline, Pfizer, Procter and Gamble, Harvard University, The Mayo Clinic, Scripps, Roche, Schering- Plough, Wyeth and others. |
